IBI363 plus chemo for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of an immunotherapy drug (IBI363) plus chemotherapy for people with advanced pancreatic cancer that has worsened after a standard first treatment. The goal is to see if the combination is safe and works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your pancreatic cancer cannot be removed by surgery or has spread to other parts of the body.
- Your cancer got worse after first treatment with gemcitabine and nab-paclitaxel (AG regimen), or you couldn't tolerate that treatment.
- You are in good physical condition (able to do daily activities without help).
- You have not been treated with immunotherapy drugs (like PD-1 or PD-L1 inhibitors) before.
- You do not have untreated or active cancer in the brain or spinal cord, and you do not have serious heart or blood vessel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a combination of radiation therapy (SBRT), two immunotherapy drugs (Ipilimumab and Sintilimab), and two chemotherapy drugs (Nab-Paclitaxel and Gemcitabine) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this treatment can control the cancer better than standard options.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
Hear when a new Pancreatic Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.